Klotho Neurosciences, Inc. Total Liabilities
Klotho Neurosciences, Inc. total liabilities. Based on the latest financial reports, Klotho Neurosciences, Inc. (KLTO) has total liabilities worth $145.89K USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See operational self-sufficiency of Klotho Neurosciences, Inc. to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Klotho Neurosciences, Inc. (2021–2024)
Total liabilities of Klotho Neurosciences, Inc. from 2021 to 2024. This chart illustrates how Klotho Neurosciences, Inc.'s total liabilities have evolved over time, based on quarterly financial data.
Klotho Neurosciences, Inc. Competitors by Total Liabilities
The table below lists competitors of Klotho Neurosciences, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
KTIS Corporation
KO:058860
|
Korea | ₩208.31 Billion |
|
Ene Technology Inc
TW:6243
|
Taiwan | NT$393.92 Million |
|
FoundPac Group Bhd
KLSE:5277
|
Malaysia | RM46.62 Million |
|
PP Properti Tbk PT
JK:PPRO
|
Indonesia | Rp8.01 Trillion |
|
TMP Steel
TWO:6248
|
Taiwan | NT$1.84 Billion |
|
Vertical Aerospace Ltd
NYSE:EVTL
|
USA | $128.35 Million |
|
Orad-M
TA:ORAD
|
Israel | ILA79.34 Million |
|
Shivalik Rasayan Limited
NSE:SHIVALIK
|
India | Rs2.20 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down Klotho Neurosciences, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Klotho Neurosciences, Inc..
Liquidity & Leverage Metrics
Klotho Neurosciences, Inc. Total Liabilities Ratios Explained
Klotho Neurosciences, Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 83.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.01 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Klotho Neurosciences, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Klotho Neurosciences, Inc. (2021–2024)
The table below shows the annual total liabilities of Klotho Neurosciences, Inc. from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.27 Million | -21.53% |
| 2023-12-31 | $1.62 Million | +19.17% |
| 2022-12-31 | $1.36 Million | +8887.60% |
| 2021-12-31 | $15.13K | -- |
About Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc. develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates consist of KLTO-101 for the treatment or prevention of Alzheimer's disease; and KLTO-202, a gene therapy product for treatment and prevention of Lou Gehrig's disease. The company was formerly known as Anew Medical, Inc. and changed it… Read more